Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
17 February, 2019 11:23 IST
Glenmark Pharmaceuticals launches Nourkrin in Russia
Source: IRIS | 01 Nov, 2018, 10.14AM
Comments  |  Post Comment

Glenmark Pharmaceuticals, a research-led globally integrated pharmaceutical company, today announced the launch of Nourkrin in Russia. Nourkrin is a globallyrenowned, clinically-proven proteoglycan replacement formula, for addressing one of the key underlying causes of hair loss in males and females.

Nourkrin Woman and Nourkrin Man will be exclusively marketed in Russia by Glenmark Impex LLC, the Russian subsidiary of Glenmark Pharmaceuticals (Q,N,C,F)* Ltd., under a licensing agreement with Denmarkheadquartered firm Pharma Medico ApS.

Glenmark had already launched Nourkrin® Woman in India in early 2018.

Nourkrin contains Marilex, a unique and proprietary scientific formula, rich in specific proteoglycans essential for hair follicle growth. Nourkrin is a proven formula based on more than 56 scientific studies and is recognized by leading regulatory agencies globally.

''We are very happy to launch Nourkrin for both women and men in Russia. It is a much awaited product, as the problem of hair loss affects quite a significant proportion of the population. Glenmark has a strong portfolio of dermatology products in Russia offering patients relief from different types of skin disorders for several decades and Nourkrin will be a great addition to this portfolio,'' said, Csaba Kantor, Senior Vice President & Head, Asia, Russia & CIS, Glenmark Pharmaceuticals.

According to a survey conducted by market research firm GfK in 2017, 18.7 million women and 14.1 million men in Russia experienced hair loss over the preceding 12 months.

Nourkrin Woman and Nourkrin Man, available as tablets, are an easy-to-use therapy compared to clinical procedures and hair sprays and creams. The product will be available through retail pharmacy chains as well as online pharmacies.

Shares of the company declined Rs 4.95, or 0.8%, to trade at Rs 616.00. The total volume of shares traded was 8,023 at the BSE (10.07 a.m., Thursday).

Comments Post comment 
 Post Comment
Name Email
Security Code type    into this box
Company Update
Lupin launches Clobazam oral suspension - 15-Feb-2019 16:37
Muthoot Finance to raise upto Rs 7.50 bn through NCDs - 14-Feb-2019 11:01
Zydus gets USFDA nod for Triamterene & Hydrochlorothiazide capsules - 13-Feb-2019 13:10
L&T Construction bags contract for construction of hospitals - 13-Feb-2019 11:56
Strides receives USFDA approval for Triamcinolone Acetonide cream - 13-Feb-2019 11:52
Lupin receives FDA approval for Fluoxetine Tablets - 12-Feb-2019 16:32
Lupin launches Tadalafil Tablets - 12-Feb-2019 16:29
C & C Constructions JV wins order worth Rs 1.24 bn from DFCCIL - 12-Feb-2019 13:44
Tata Motors group global wholesales up 12% in January 2019 - 12-Feb-2019 13:39
Alembic Pharma announces completion of USFDA inspection at Aleor Dermaceuticals - 12-Feb-2019 10:37
L&T Hydrocarbon Engineering bags order from Sonatrach-Algeria - 12-Feb-2019 10:32
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer